Richard M Kostrzewa
Overview
Explore the profile of Richard M Kostrzewa including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
84
Citations
858
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Kostrzewa R
J Neural Transm (Vienna)
. 2022 Mar;
129(5-6):445-461.
PMID: 35279767
The neurotoxin 6-hydroxydopamine (6-OHDA), following pretreatment with the norepinephrine transport inhibitor desipramine, selectively destroys dopaminergic neurons. When given to rats, neonatal 6-OHDA (n6-OHDA) crosses the blood-brain barrier to destroy 90-99%...
2.
Kostrzewa J, Kostrzewa R
Neurotox Res
. 2020 Jan;
37(3):543-552.
PMID: 31939043
Serotoninergic nerves are known to modulate sensitization of dopamine receptors (DA-R) in a rodent model of Parkinson's disease (PD). However, serotoninergic nerves are not known to have a prominent role...
3.
Kostrzewa R, Wydra K, Filip M, Crawford C, McDougall S, Brown R, et al.
J Pharmacol Exp Ther
. 2018 Jun;
366(3):519-526.
PMID: 29921706
Abnormality of dopamine D receptor (DR) function, often observed as DR supersensitivity (DRSS), is a commonality of schizophrenia and related psychiatric disorders in humans. Moreover, virtually all psychotherapeutic agents for...
4.
Cox P, Kostrzewa R, Guillemin G
Neurotox Res
. 2017 May;
33(1):178-183.
PMID: 28540663
The cyanobacterial toxin β-N-methylamino-L-alanine (BMAA) now appears to be a cause of Guamanian amyotrophic lateral sclerosis/parkinsonism dementia complex (ALS/PDC). Its production by cyanobacteria throughout the world combined with multiple mechanisms...
5.
Archer T, Kostrzewa R
Curr Top Behav Neurosci
. 2016 Feb;
29:1-40.
PMID: 26857462
Over the past 60 years, a large number of selective neurotoxins were discovered and developed, making it possible to animal-model a broad range of human neuropsychiatric and neurodevelopmental disorders. In...
6.
Archer T, Kostrzewa R
Curr Top Behav Neurosci
. 2016 Jan;
29:333-351.
PMID: 26728168
Physical exercise offers a highly effective health-endowering activity as has been evidence using rodent models of Parkinson's disease (PD). It is a particularly useful intervention in individuals employed in sedentary...
7.
Kostrzewa R
Curr Top Behav Neurosci
. 2015 Dec;
29:43-50.
PMID: 26660536
6-hydroxydopa (6-OHDOPA) was synthesized with the expectation that it would be able to cross the blood-brain barrier to be enzymatically decarboxylated to 6-hydroxydopamine (6-OHDA), the newly discovered neurotoxin for noradrenergic...
8.
Kostrzewa R, Nowak P, Brus R, Brown R
Neurochem Res
. 2015 Nov;
41(1-2):183-92.
PMID: 26547196
Repeated daily treatments of perinatal rats with the dopamine D2-receptor (D2-R) agonist quinpirole for a week or more produces the phenomenon of 'priming'-gradual but long-term sensitization of D2-R. In fact...
9.
Kostrzewa J, Kostrzewa R, Kostrzewa R, Brus R, Nowak P
Curr Top Behav Neurosci
. 2015 Oct;
29:279-293.
PMID: 26475157
The neonatally 6-hydroxydopamine (n6-OHDA)-lesioned rat has been the standard for 40 years, as an animal model of attention-deficit hyperactivity disorder (ADHD). Rats so lesioned during postnatal ontogeny are characterized by ...
10.
Kostrzewa J, Kostrzewa R, Kostrzewa R, Brus R, Nowak P
Curr Top Behav Neurosci
. 2015 Oct;
29:313-332.
PMID: 26475156
The classic rodent model of Parkinson's disease (PD) is produced by unilateral lesioning of pars compacta substantia nigra (SNpc) in adult rats, producing unilateral motor deficits which can be assessed...